36150 Federal Register / Vol. 65, No. 110 / Wednesday, June 7, 2000 / Notices

relative’s next-of-kin. The annual

reporting burden is presented in the

table below. The annualized cost to

respondents is estimated at: $23,700.

There are no Capital Costs to report.

There are no Operating or Maintenance

Costs to report.

Type of respondents

Estimate number of respondents

Estimated

number of responses per

respondent

Average burden hours per

response

Estimated total

annual burden

hours requested

Adults age 25 to 64 ......................................................................................... 1800 1 0.835 1503

Adults relatives or their next-of kin .................................................................. 5190 1 0.167 867

Total .......................................................................................................... ........................ ........................ ........................ 2370

Request for Comments:

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information is

necessary for the proper performance of

the function of the agency, including

whether the information will have

practical utility; (2) The accuracy of the

agency’s estimate of the burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used; (3)

Ways to enhance the quality, utility,

sand clarity of the information to be

collected; and (4) Ways to minimize the

burden of the collection of information

on those who are to respond, including

the use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology.

For Further Information:

To request more information on the

proposed project or to obtain a copy of

the data collection plans and

instruments, contact Dr. Louise

Wideroff, Project Officer, Applied

Research Program, National Cancer

Institute, 6130 Executive Blvd. EPN

4010, Bethesda, MD 20892, or call nontoll-free number (301) 435–6823 or Email your request, including your

address to: wideroff@nih.gov.

Comments Due Date:

Comments regarding this information

collection are best assured of having

their full effect if received on or before

August 7, 2000.

Dated: May 30, 2000.

Reesa Nichols,

OMB Project Liaison Officer.

[FR Doc. 00–14340 Filed 6–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by

contacting Marlene Shinn, J.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7056 ext. 285; fax: 301/402–0220;

e-mail: ms482m@nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Direct C–14 Oxidation of Opioids

Andrew Coop, Kenner C. Rice (NIDDK)

DHHS Reference No. E–032–99/1 filed

04 May 2000

Opioid agonist drugs including the

14-hydroxy derivatives are utilized in

the treatment of pain. The 14-hydroxy

substituted opioid antagonists have also

been found to be useful in the treatment

of opiate abuse, opiate overdose and

alcohol addiction. In addition, there are

certain derivatives which have been

found to be useful in the prevention of

tolerance to morphine and as

immunosuppressants. The 14-hydroxy

agonist and antagonist drugs are

produced by a multistep process from

the starting material, thebaine, which is

a minor constituent of opium and is

generally in short supply. The demand

for these products has resulted in a

steadily increasing cost for thebaine and

thebaine derivatives.

The present technology consists of a

new and practical, nonchromatographic

method of preparing 14-

hydroxycodeinone by the direct

oxidation of codeinone with cobalt (III)

acetate (easily prepared in situ). The

technology gives a 51% unoptimized

yield of 14-hydroxycodeinone easily

isolated by extractive workup and direct

crystallization. This process is

ultimately based on morphine (which is

by far the major constituent and

cheapest of the opium alkaloids)

through the sequence: morphine to

codeine to codeinone to 14-

hydroxycodeinone. This technology is

not limited by the availability of

thebaine and thus offers more efficient

production of the 14-hydroxy

derivatives from opium.

Use of Oligonucleotides To Target

Nucleic Acid Sequences Encoding

Apolipoprotein B To Decrease Serum

Apolipoprotein B and Cholesterol

Levels

Thomas L Eggerman (FDA), Amy

Patterson, Paul F. Torrence (NIDDK),

Julie K Rhie

DHHS Reference No. E–236–98/0 filed

12 Oct 1999

Coronary heart disease is caused by

the atherosclerotic narrowing of the

coronary arteries affecting nearly 14

million persons in the United States.

Approximately 480,000 deaths in 1995

were caused by the disease and it is the

leading cause of death in the United

States today. Two of the established

causes of atheroscleorosis include

elevated cholesterol levels and

elevations of the major protein

responsible for carrying cholesterol—

apolipoprotein B (apoB). Optimal

therapy, however is still not available

for the most severely affected patients,

in particular those with familial

hypercholesterolemia and those with

elevated apoB levels.

Federal Register / Vol. 65, No. 110 / Wednesday, June 7, 2000 / Notices 36151

The NIH announces a new gene

therapy approach which will lower the

risk for atheroscleoric heart disease by

decreasing plasma cholesterol and apoB

levels. Our researchers have shown that

antisense DNA oligonucleotides targeted

for apoB decreased apoB mRNA in a

human liver cell line by up to 80%. This

in turn has led to a new gene therapy

which utilizes a vector designed to

produce antisense mRNA targeted for

apoB. The result is a decrease in liver

apoB production, which is the major

source of circulating apoB. These

oligonucleotides and oligonucleotide

analogs are a novel and useful way of

reducing low density lipoprotein (LDL)

in patients, as well as for research and

diagnostic purposes.

T20/D178 and T21/D107 Are Activators

of Human Phagocyte Formyl Peptide

Receptors

Ji Ming Wang (NCI), Joost J Oppenheim

(NCI), Shao-Bo Su, Wang-Hua Gong,

Philip M. Murphy (NIAID), Ji-Liang

Gao (NIAID)

DHHS Reference No. E–164–99/0 filed

05 May 1999

The use of immunotherapy to treat

inflammatory diseases is prescribed to

thousands each and every year. In use

currently are steroidal and non-steroidal

anti-inflammatory drugs, which have

serious side effects including: adrenal

suppression, gastrointestinal disorders,

increased susceptibility to infections,

fluid retention and bone loss.

The NIH announces a new technology

which can be used in drug discovery

dealing with the modulation of the

immune response. This technology

identifies two polypeptides, T20/DP178

and T21/DP107, which are peptide

domains of the HIV–1 envelope protein

and are potent chemoattractants and

activators of human peripheral blood

phagocytes (monocytes and neutrophils)

but not T lymphocytes. These

polypeptides have been determined to

interact with the Formyl Peptide

Receptors (FPR), which in turn upregulates the immune response by

inducing cell migration and calcium

mobilization. The activation of FPR

class receptors by their agonists also

results in desensitization of cell

responses to other chemotactic factors.

By identifying analogs to T20/DP178

and T21/DP107 and then evaluating

their ability to bind to the FPR, one will

be able to determine if the analog is a

good candidate for either inhibiting or

activating the immune response.

Dated: May 30, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–14343 Filed 6–6–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Clinical Center; Notice of Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Board of Governors of the Warren Grant

Magnuson Clinical Center.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: Board of Governors of

the Warren Grant Magnuson Clinical Center

Executive Committee.

Date: July 21, 2000.

Time: 8:30 am to 1:30 pm.

Agenda: Topics Related to Clinical Center

Budget.

Place: National Institutes of Health,

Clinical Center Medical Board Room, 2C116,

9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Maureen E. Gormley,

Executive Secretary, Warren Grant Magnuson

Clinical Center, National Institutes of Health,

Building 10, Room 2C146, Bethesda, MD

20892, 301/496–2897.

Dated: May 31, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–14332 Filed 6–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in section 552b(c)(4)

and 552b(c)(6), Title 5 U.S.C., as

amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Diet,

Lifestyle and Cancer in U.S. Special

Populations.

Date: June 29, 2000.

Time: 12 pm to 1:30 pm.

Agenda: To review and evaluate grant

applications.

Place: Executive Plaza North, 6130

Executive Boulevard, Conference Room E,

Rockville MD 20852, (Telephone Conference

Call).

Contact Person: Gerald G. Lovinger,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8070, Rockville, MD

20892–7405, 301/496–7987.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of health,

HHS)

Dated: May 31, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–14333 Filed 6–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The contract proposals and